WAM
RNAC icon

WNY Asset Management’s Cartesian Therapeutics RNAC Stock Holding History

WNY Asset Management’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-342
Closed -$6.66K – 247
2024
Q1 		$6.66K Hold
342
– – ﹤0.01% 233
2023
Q4 		$7.07K Hold
342
– – ﹤0.01% 217
2023
Q3 		$10.9K Hold
342
– – ﹤0.01% 205
2023
Q2 		$11.5K Hold
342
– – ﹤0.01% 193
2023
Q1 		$14.2K Hold
342
– – ﹤0.01% 186
2022
Q4 		$11.6K Sell
342
-25
-7% -$1.06K ﹤0.01% 184
2022
Q3 		$18K Hold
367
– – 0.01% 164
2022
Q2 		$14K Hold
367
– – ﹤0.01% 163
2022
Q1 		$13K Sell
367
-26
-7% -$1.63K ﹤0.01% 165
2021
Q4 		$39K Hold
393
– – 0.01% 168
2021
Q3 		$49K Buy
+393
New +$47.5K 0.02% 154

Other funds holding RNAC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

WNY Asset Management's RNAC Position: Q2 2024 in Review

WNY Asset Management sold out of Cartesian Therapeutics (RNAC) in Q2 2024, closing a stake of 342 shares — an estimated $6.66K sold.

WNY Asset Management first reported a position in RNAC in Q3 2021 and held it in 11 quarters. The position peaked at $49K in Q3 2021. 61 funds tracked by Wall St. Rank hold RNAC as of Q2 2024.

  • WNY Asset Management reported no remaining Cartesian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • WNY Asset Management sold 342 Cartesian Therapeutics shares in Q2 2024, an estimated $6.66K.
  • WNY Asset Management first reported a position in Cartesian Therapeutics in Q3 2021 and held it in 11 quarters.
  • WNY Asset Management's Cartesian Therapeutics position peaked at $49K in Q3 2021.
  • 61 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2024.

Based on WNY Asset Management's 13F filing for Q2 2024, filed 12 Aug 2024.